advanced cutaneous squamous cell carcinoma
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss
Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Sanofi announces phase 3 study data for infantile-onset Pompe disease
Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form
Sanofi’s Cenrifki approved in Europe for secondary progressive MS without relapses
SPMS is a debilitating stage of MS where patients experience increasing levels of disability
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Sanofi appoints Paulo Fontoura as Global Head of R&D
Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche
Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector
It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Regeneron agrees research collaboration with Parabilis Medicines
Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties
Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes
The treatment can be used to delay the onset of clinical type 1 diabetes